[1] Schuppan D, Afdhal N H. Liver cirrhosis[J]. Lancet, 2008, 371(9615):838-851.
[2] De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4):959-974.
[3] 中华医学会消化病学分会. 中国肝硬化临床诊治共识意见[J]. 中华消化杂志, 2023, 43(4):227-247.
[4] Premkumar M, Dhiman R K, Duseja A, et al. Recompensation of chronic hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: Prospective cohort study from a hepatitis C virus elimination program[J]. Gastroenterology, 2024, 167(7):1429-1445.
[5] Krassenburg L A P, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity[J]. J Hepatol, 2021, 74(5):1053-1063.
[6] Sánchez-Torrijos Y, Fernández-Alvarez P, Rosales J M, et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C[J]. J Hepatol, 2025, 83(3):652-661.
[7] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6):1564-1572.
[8] Deng Y, Kang H Y, Xiang H L, et al. Durability and on-treatment predictors of recompensation in entecavir-treated patients with hepatitis B and decompensated cirrhosis[J]. JHEP Rep, 2024, 6(7):101091.
[9] Hui V W K, Wong G L H, Wong V W S, et al. Baveno Ⅶ criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis[J]. JHEP Rep, 2023, 5(9):100814.
[10] Hofer B S, Simbrunner B, Hartl L, et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis[J]. Clin Gastroenterol Hepatol, 2023, 21(9):2308-2317.e7.
[11] Pose E, Torrents A, Reverter E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement[J]. J Hepatol, 2021, 75(2):275-283.
[12] Hofer B S, Simbrunner B, Hartl L, et al. Hepatic recompensation according to Baveno Ⅶ criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023, 43(10):2220-2231.
[13] Jagtap N, Kalapala R, Katakwar A, et al. Endoscopic sleeve gastroplasty: Minimally invasive treatment for non-alcoholic fatty liver disease and obesity[J]. Indian J Gastroenterol, 2021, 40(6):572-579.
[14] Wang Z Y, Sheng L, Yang Y, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: Real-world experience and a comprehensive review[J]. Clin Rev Allergy Immunol, 2017, 52(3):424-435.
[15] Hofer B S, Burghart L, Halilbasic E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis[J]. Aliment Pharmacol Ther, 2024, 59(8):962-972.
[16] Tiede A, Maasoumy B. TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure?[J]. Clin Mol Hepatol, 2025, 31(2):e176-e179.
[17] Tiede A, Stockhoff L, Liu Z, et al. Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis[J]. Clin Mol Hepatol, 2025, 31(1):240-255.
[18] Kornfehl A, Tiede A, Hemetsberger P, et al. Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis[J]. JHEP Rep, 2024, 7(4):101308.
[19] Sánchez J, González S, Poyatos P, et al. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis[J]. Liver Int, 2024, 44(11):3072-3082.
[20] El-Sherif O, Jiang Z G, Tapper E B, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection[J]. Gastroenterology, 2018, 154(8):2111-2121.e8.
[21] Kim T H, Um S H, Lee Y S, et al. Determinants of recompensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy[J]. Aliment Pharmacol Ther, 2022, 55(1):83-96.
[22] Vutien P, Kim N J, Moon A M, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication[J]. Aliment Pharmacol Ther, 2024, 59(3):361-371.
[23] Singal A K, Panneerselvam D, Arab J P, et al. Delisting from liver transplant list for improvement and recompensation among decompensated patients at one year[J]. Am J Gastroenterol, 2024, 120(9):2086-2092. |
